Champions Oncology Q1 Revenue Up 8.8%, Margin Jumps to 51%, Adjusted EBITDA Soars
CSBR is trading near its 52-week low of $4.83 (5.5% above the low).
Summary
Champions Oncology reported fiscal Q1 revenue of $15.2 million, up 8.8% year-over-year, with oncology services margin improving to 51% and adjusted EBITDA jumping to $671,000 from $59,000.
Key Events · Earnings and Guidance · CSBR
-
Q1 Revenue Up 8.8%
Total oncology revenue reached $15.2 million, up from $14.0 million in the prior-year quarter, driven by higher core research services revenue and increased data license revenue.
-
Margin Expansion to 51%
Oncology services margin improved to 51% from 43% year-over-year, reflecting higher revenue and lower third-party radiolabeling costs.
-
Adjusted EBITDA Jumps 11x
Adjusted EBITDA increased to $671,000 from $59,000 in the prior-year quarter, demonstrating operating leverage as revenue grows.
-
Net Loss Narrows
GAAP net loss was $426,000 compared to $466,000 a year ago, with stock-based compensation of $766,000 and depreciation of $314,000 included in the quarter.
Analysis · CSBR · Life Sciences
Champions Oncology delivered a strong fiscal Q1 with revenue up 8.8% to $15.2 million and oncology services margin expanding to 51% from 43%. Adjusted EBITDA surged to $671,000 from just $59,000 a year ago, showing real operating leverage. The company still lost $426,000 on a GAAP basis, but the trend is clearly improving. Cash stands at $4.4 million with no debt, though the balance sheet remains tight relative to the $15.6 million in quarterly operating expenses.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1963 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.14%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CSBR was trading at $5.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $70.9M. The 52-week trading range was $4.83 to $8.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.